Bevacizumab-induced hand-foot syndrome: circumscribed type.
Munehiro
A
A
Yoneda
K
K
Nakai
K
K
Demitsu
T
T
Moriue
T
T
Moriue
J
J
Yokoi
I
I
Fujita
N
N
Matsuura
N
N
Ishikawa
S
S
Yokomise
H
H
Kubota
Y
Y
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001768:Blister / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab